Status | Study |
Enrolling by invitation |
Study Name: Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease? Condition: Von Hippel-Lindaus Disease Date: 2014-08-01 |
Active, not recruiting |
Study Name: Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System Condition: Hemangioblastoma (HB) of the Central Nervous System (CNS) Date: 2014-04-16 Interventions: Other: evaluation of anxiety with psychosocial scales |
Enrolling by invitation |
Study Name: Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) Condition: Von Hippel-Lindau Disease Date: 2014-04-05 Interventions: Drug: Vorinostat |
Terminated |
Study Name: TKI 258 in Von Hippel-Lindau Syndrome (VHL) Condition: Von Hippel-Lindau Syndrome Date: 2010-12-22 Interventions: Drug: Dovitinib 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cy |
Terminated |
Study Name: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease Condition: Hemangioblastomas Von Hippel Lindau Disease Date: 2009-11-16 Interventions: Drug: Avastin Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months |
Completed |
Study Name: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Condition: Von Hippel-Lindau Disease Hemangioblastoma Date: 2009-09-02 Interventions: Other: 89Zr bevacizumab PET scan Patients will be injected intravenously with 37 MBq, protein dose 5 mg |
Completed |
Study Name: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Condition: CNS Cancer Meningioma Intracranial Hemangiopericytoma Date: 2007-12-26 Interventions: Drug: Sunitinib The study drug will be administered on an outpatient basis. The starting dose will be 50 |
Terminated |
Study Name: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Condition: Von Hippel-Lindau Syndrome Renal Cell Carcinoma Date: 2006-05-26 Interventions: Drug: SU011248 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle). |
Completed |
Study Name: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 Condition: Von Hippel-Lindau Disease CNS Hemangioblastoma Date: 2003-01-21 Interventions: Drug: PTK787/ZK 222584 |
Active, not recruiting |
Study Name: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Condition: Hemangioblastoma Hippel Lindau Disease Date: 2000-06-06 |